EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY

BACKGROUND: International consensus and the 2021 WHO classification recognize eight molecular subtypes among Group 3/4 medulloblastoma (representing ~60% of tumors). However, very few clinical centers worldwide possess the technical capabilities to determine DNA-methylation patterns or other molecul...

Descripción completa

Detalles Bibliográficos
Autores principales: Delaidelli, Alberto, Dunham, Christopher, Santi, Maria Rita, Negri, Gian Luca, Triscott, Joanna, Zheludkova, Olga, Golanov, Andrey, Ryzhova, Marina, Okonechnikov, Konstantin, Schrimpf, Daniel, Stichel, Damian, von Deimling, Andreas, Kool, Marcel, Pfister, Stefan, Ramaswamy, Vijay, Korshunov, Andrey, Taylor, Michael, Sorensen, Poul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Embryonal Tumors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168220/
http://dx.doi.org/10.1093/neuonc/noab090.039

Ejemplares similares

Ejemplares similares